Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism
OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial
Pfizer's Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure
THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.
Wednesday, September 17th, 2014 – Fenway Park, Boston, MA The Redefining Early Stage Investments (RESI) Conference is reinventing the way investors and entrepreneurs connect and share...
LIFE SCIENCES VENTURE CAPITAL INVESTMENTS SOAR IN Q2 TO HIGHEST LEVEL SINCE 2007, ACCORDING TO THE MONEYTREE REPORT
Study Using REGENX Biosciences' NAV(R) Vector Highlights Potential for AAV-Mediated Gene Therapy to Treat Lysosomal Storage Diseases That Affect the CNS
Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration
Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody, a component of Roche's immunotherapy assay
Robust antibody gives researchers early access to PD-L1 and immunotherapy tissue staining for Research Use Only (RUO) applications